<DOC>
	<DOCNO>NCT02996812</DOCNO>
	<brief_summary>This study design evaluate safety , efficacy , pharmacokinetic profile single ascending dos exendin 9-39 administer subcutaneous route subject post-bariatric hypoglycemia .</brief_summary>
	<brief_title>Evaluation Single Ascending Doses Subcutaneous Exendin 9-39 Patients With Post-Bariatric Hypoglycemia</brief_title>
	<detailed_description>Post-Bariatric Hypoglycemia ( PBH ) debilitate rare disease afflict 0.2-6.9 % post-bariatric patient , characterize repeat severe hypoglycemic episode neuroglycopenic symptom mark disability . There effective medical therapy . While cause know , exaggerated postprandial secretion glucagon-like peptide-1 ( GLP-1 ) result alter nutrient transit likely play major role . GLP-1 incretin hormone secrete primarily distal ileum contribute postprandial glucose regulation . Exendin 9-39 ( Ex9 ) specific GLP-1 receptor antagonist , give via continuous IV infusion , show effectively prevent postprandial hypoglycemia patient PBH . Subcutaneous ( SC ) injection Ex9 may represent safe , effective practical therapeutic approach treat PBH .</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Hyperinsulinism</mesh_term>
	<criteria>Postbariatric surgery 6 month prior sign inform consent Reported history Whipple 's triad : occurrence hypoglycemic symptom associate blood glucose ≤55 mg/dL , resolution glucose carbohydrate administration . Symptomatic hypoglycemia baseline/screening OGTT , define presence plasma glucose ≤55 mg/dL concomitant autonomic and/or neuroglycopenic symptom . Patients currently use sulfonylureas medication may interfere glucose metabolism within 5 halflives drug . Participation clinical investigation within 4 week prior dose History current insulinoma Active infection significant acute illness within 2 week prior dose Female patient pregnant lactating Women childbearing potential utilizing effective contraceptive method Inadequate end organ function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Post-bariatric hypoglycemia</keyword>
	<keyword>Non-insulinoma pancreatogenous hypoglycemia syndrome</keyword>
	<keyword>Late dumping syndrome</keyword>
</DOC>